Business
Transaction Update & Notice of Intention to Delist
Roquefort Therapeutics plc is proceeding with a significant transaction involving the acquisition of worldwide exclusive rights to AO-252, a cancer drug candidate targeting TACC3, from Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. This acquisition is contingent upon the company's shares being admitted to the AIM market of the London Stock Exchange. Concurrently, Roquefort Therapeutics intends to delist its ordinary shares from the Main Market of the London Stock Exchange, with the delisting expected to become effective in at least 20 business days. Documentation for the associated equity fundraise, the AIM Admission Document, and a Notice of General Meeting are being finalized and are expected to be published shortly. Disclaimer*
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\n25 February 2026\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\n \nTransaction Update & Intention to delist from the Main Market\n \nRoquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, is pleased to announce the proposed transaction with Coiled Therapeutics, Inc. (\"Coiled USA\") and A2A Pharmaceuticals, Inc. (\"A2A Pharma\"), pursuant to which the Company will acquire the worldwide exclusive rights to AO-252, a drug candidate that binds to TACC3 for the treatment of cancers with unmet medical needs is nearing completion (the \"Acquisition\") which is conditional on the admission of the Company's issued and to be issued share capital being admitted to the AIM market of London Stock Exchange (\"AIM Market\") (\"Admission\").\n \nThe Company and its professional advisers are currently finalising documentation relating to the equity fundraise which is being undertaken in conjunction with the Acquisition (the \"Fundraise\"), along with the Company's AIM Admission Document and Notice of General Meeting, which is expected to be published in the coming days (see below) (the, Fundraise, Acquisition and Admission together referred to as the \"Transaction\").\n \nIntention to delist from the Main Market\nIn conjunction with the Transaction, the Company announces its intention to cancel the listing of the Company's ordinary shares on the Equity Shares (Transition) category of the Official List of the Financial Conduct Authority (\"FCA\") and to cancel the trading of its ordinary shares on the Main Market of the London Stock Exchange (the \"Delisting\").\n \nAs a company listed on the Equity Shares (Transition) category, the Company is not required to obtain the approval of its shareholders for the Delisting but is required under UK Listing Rule 21.2.17 to give at least 20 business days' notice of the intended cancellation.\n \nAccordingly, the Company has requested that: (i) the FCA cancel the listing of its ordinary shares on the Official List of the FCA; and (ii) the London Stock Exchange cancels the admission to trading of the ordinary shares on the Main Market for listed securities of the London Stock Exchange.\n \nIt is anticipated that the Delisting will become effective in not less than 20 business days. Full details regarding the spe...